182 related articles for article (PubMed ID: 19365402)
1. CYP2D6 genotype and its relationship with metoprolol dose, concentrations and effect in patients with systolic heart failure.
Sharp CF; Gardiner SJ; Jensen BP; Roberts RL; Troughton RW; Lainchbury JG; Begg EJ
Pharmacogenomics J; 2009 Jun; 9(3):175-84. PubMed ID: 19365402
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension.
Zineh I; Beitelshees AL; Gaedigk A; Walker JR; Pauly DF; Eberst K; Leeder JS; Phillips MS; Gelfand CA; Johnson JA
Clin Pharmacol Ther; 2004 Dec; 76(6):536-44. PubMed ID: 15592325
[TBL] [Abstract][Full Text] [Related]
3. An investigation of CYP2D6 genotype and response to metoprolol CR/XL during dose titration in patients with heart failure: a MERIT-HF substudy.
Batty JA; Hall AS; White HL; Wikstrand J; de Boer RA; van Veldhuisen DJ; van der Harst P; Waagstein F; Hjalmarson Å; Kjekshus J; Balmforth AJ;
Clin Pharmacol Ther; 2014 Mar; 95(3):321-30. PubMed ID: 24193112
[TBL] [Abstract][Full Text] [Related]
4. Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study.
Fux R; Mörike K; Pröhmer AM; Delabar U; Schwab M; Schaeffeler E; Lorenz G; Gleiter CH; Eichelbaum M; Kivistö KT
Clin Pharmacol Ther; 2005 Oct; 78(4):378-87. PubMed ID: 16198657
[TBL] [Abstract][Full Text] [Related]
5. Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics.
Kirchheiner J; Heesch C; Bauer S; Meisel C; Seringer A; Goldammer M; Tzvetkov M; Meineke I; Roots I; Brockmöller J
Clin Pharmacol Ther; 2004 Oct; 76(4):302-12. PubMed ID: 15470329
[TBL] [Abstract][Full Text] [Related]
6. beta-Adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure.
Terra SG; Pauly DF; Lee CR; Patterson JH; Adams KF; Schofield RS; Belgado BS; Hamilton KK; Aranda JM; Hill JA; Yarandi HN; Walker JR; Phillips MS; Gelfand CA; Johnson JA
Clin Pharmacol Ther; 2005 Mar; 77(3):127-37. PubMed ID: 15735607
[TBL] [Abstract][Full Text] [Related]
7. Relation of ADRB1, CYP2D6, and UGT1A1 polymorphisms with dose of, and response to, carvedilol or metoprolol therapy in patients with chronic heart failure.
Baudhuin LM; Miller WL; Train L; Bryant S; Hartman KA; Phelps M; Larock M; Jaffe AS
Am J Cardiol; 2010 Aug; 106(3):402-8. PubMed ID: 20643254
[TBL] [Abstract][Full Text] [Related]
8. Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects.
Wuttke H; Rau T; Heide R; Bergmann K; Böhm M; Weil J; Werner D; Eschenhagen T
Clin Pharmacol Ther; 2002 Oct; 72(4):429-37. PubMed ID: 12386645
[TBL] [Abstract][Full Text] [Related]
9. The influence of CYP2D6 genotype on trough plasma perhexiline and cis-OH-perhexiline concentrations following a standard loading regimen in patients with myocardial ischaemia.
Davies BJ; Coller JK; James HM; Somogyi AA; Horowitz JD; Sallustio BC
Br J Clin Pharmacol; 2006 Mar; 61(3):321-5. PubMed ID: 16487226
[TBL] [Abstract][Full Text] [Related]
10. [Rationale and methods of the UNAMET study (dose- and CYP2D6-genotype-dependent adverse drug reactions of metoprolol)--a contribution to quality improvement in pharmacotherapy].
Fux R; Meisner C; Schwab M; Lorenz G; Mörike K; Gleiter CH
Z Arztl Fortbild Qualitatssich; 2004 Nov; 98(8):689-94. PubMed ID: 15646732
[TBL] [Abstract][Full Text] [Related]
11. Impact of the CYP2D6 genotype on the clinical effects of metoprolol: a prospective longitudinal study.
Rau T; Wuttke H; Michels LM; Werner U; Bergmann K; Kreft M; Fromm MF; Eschenhagen T
Clin Pharmacol Ther; 2009 Mar; 85(3):269-72. PubMed ID: 19037197
[TBL] [Abstract][Full Text] [Related]
12. Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in beta-blocker users.
Bijl MJ; Visser LE; van Schaik RH; Kors JA; Witteman JC; Hofman A; Vulto AG; van Gelder T; Stricker BH
Clin Pharmacol Ther; 2009 Jan; 85(1):45-50. PubMed ID: 18784654
[TBL] [Abstract][Full Text] [Related]
13. Depot haloperidol treatment in outpatients with schizophrenia on monotherapy: impact of CYP2D6 polymorphism on pharmacokinetics and treatment outcome.
Panagiotidis G; Arthur HW; Lindh JD; Dahl ML; Sjöqvist F
Ther Drug Monit; 2007 Aug; 29(4):417-22. PubMed ID: 17667795
[TBL] [Abstract][Full Text] [Related]
14. Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity.
Hamelin BA; Bouayad A; Méthot J; Jobin J; Desgagnés P; Poirier P; Allaire J; Dumesnil J; Turgeon J
Clin Pharmacol Ther; 2000 May; 67(5):466-77. PubMed ID: 10824625
[TBL] [Abstract][Full Text] [Related]
15. CYP2D6 Genetic Variation and Beta-Blocker Maintenance Dose in Patients with Heart Failure.
Luzum JA; Sweet KM; Binkley PF; Schmidlen TJ; Jarvis JP; Christman MF; Sadee W; Kitzmiller JP
Pharm Res; 2017 Aug; 34(8):1615-1625. PubMed ID: 28181117
[TBL] [Abstract][Full Text] [Related]
16. The relevance of CYP2D6 genetic polymorphism on chronic metoprolol therapy in cardiovascular patients.
Ismail R; Teh LK
J Clin Pharm Ther; 2006 Feb; 31(1):99-109. PubMed ID: 16476126
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of mirtazapine: enantioselective effects of the CYP2D6 ultra rapid metabolizer genotype and correlation with adverse effects.
Brockmöller J; Meineke I; Kirchheiner J
Clin Pharmacol Ther; 2007 May; 81(5):699-707. PubMed ID: 17329996
[TBL] [Abstract][Full Text] [Related]
18. Influence of CYP2D6 genotype on metoprolol plasma concentration and beta-adrenergic inhibition during long-term treatment: a comparison with bisoprolol.
Nozawa T; Taguchi M; Tahara K; Hashimoto Y; Igarashi N; Nonomura M; Kato B; Igawa A; Inoue H
J Cardiovasc Pharmacol; 2005 Nov; 46(5):713-20. PubMed ID: 16220080
[TBL] [Abstract][Full Text] [Related]
19. Effects of the CYP2D6*10 alleles and co-medication with CYP2D6-dependent drugs on risperidone metabolism in patients with schizophrenia.
Yagihashi T; Mizuno M; Chino B; Sato Y; Sakuma K; Takebayashi T; Takao T; Kosaki K
Hum Psychopharmacol; 2009 Jun; 24(4):301-8. PubMed ID: 19387994
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic and pharmacodynamic interactions between metoprolol and dronedarone in extensive and poor CYP2D6 metabolizers healthy subjects.
Damy T; Pousset F; Caplain H; Hulot JS; Lechat P
Fundam Clin Pharmacol; 2004 Feb; 18(1):113-23. PubMed ID: 14748763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
